Diabetic Retinopathy: A Serious Complication of Diabetes

Diabetic retinopathy is a serious, vision-threatening complication of diabetes mellitus that results from chronic hyperglycemia-induced damage to the microvasculature of the retina. It is the leading cause of preventable blindness among working-age adults in developed countries and a major public health concern globally.

The pathophysiology centers on prolonged exposure to elevated blood glucose levels, which triggers oxidative stress, inflammation, and abnormal activation of protein kinase C and the polyol pathway. These mechanisms collectively lead to pericyte loss, basement membrane thickening, endothelial dysfunction, and breakdown of the blood–retinal barrier—culminating in microaneurysms, intraretinal hemorrhages, capillary nonperfusion, and pathological neovascularization.

Clinically, diabetic retinopathy is classified into two main stages: nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). NPDR ranges from mild—characterized by isolated microaneurysms—to severe—marked by extensive intraretinal microvascular abnormalities (IRMA), venous beading, and multiple hemorrhages. PDR represents advanced disease, defined by the growth of fragile, leaky new blood vessels on the retinal surface or optic disc, which carry high risks of vitreous hemorrhage, tractional retinal detachment, and neovascular glaucoma.

Early detection through regular, dilated fundus examinations—and increasingly, ultra-widefield imaging and optical coherence tomography angiography—is critical, as the condition is often asymptomatic until irreversible structural damage has occurred. Management hinges on strict glycemic, blood pressure, and lipid control; timely referral to ophthalmology; and evidence-based interventions including anti-VEGF intravitreal injections, panretinal photocoagulation, and vitrectomy when indicated.

Prevention remains paramount: comprehensive diabetes care, patient education on screening adherence, and multidisciplinary collaboration between endocrinologists, primary care providers, and retinal specialists are essential to mitigate visual morbidity and preserve quality of life.